Stock comparison
Hologic
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HOLX
Hologic
Market cap
$16.97B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HOLX | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 55C | 75B | IDXX |
| Benjamin Graham | 85A | 80A | HOLX |
| Philip Fisher | 42D | 75B | IDXX |
| Peter Lynch | 22F | 71B | IDXX |
| Joel Greenblatt | 45D | 83C | IDXX |
| Charlie Munger | 52C | 87A | IDXX |
| Terry Smith | 52D | 84A | IDXX |
Side-by-side metrics
| Metric | HOLX | IDXX |
|---|---|---|
| Market cap | $16.97B | $44.12B |
| P/E (TTM) | 31.4x | 39.0x |
| EV/EBIT | 24.2x | 31.6x |
| ROIC (TTM) | 7.18% | 40.66% |
| Gross margin | 52.82% | 62.05% |
| Net margin | 13.18% | 24.63% |
| Revenue CAGR 5y | -7.63% | 7.56% |
| EPS CAGR 5y | -23.45% | 10.79% |
| Debt / Equity | 0.5x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HOLX leads on
- Debt / Equity0.5xvs 0.7x+31%
- EV/EBIT24.2xvs 31.6x+23%
- P/E (TTM)31.4xvs 39.0x+20%
IDXX leads on
- Revenue CAGR 5y7.56%vs -7.63%+199%
- EPS CAGR 5y10.79%vs -23.45%+146%
- ROIC (TTM)40.66%vs 7.18%+82%
- Market cap$44.12Bvs $16.97B+62%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.